News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Disclaimer – pledpharma.com

November 4, 2020

The information contained in this section of the website contains information relating to an offer to existing shareholders and the public in Sweden to subscribe for shares in PledPharma AB (publ) (the “Company“). This information may not be accessed by residents of certain countries based on applicable securities law regulations.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WHOLLY OR PARTLY, IN THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS), ANY STATE OF THE UNITED STATES INCLUDING THE DISTRICT OF COLUMBIA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories and possessions), any state of the United States including the District of Columbia (the “United States“), Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, Switzerland, South Africa, South Korea and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities of the Company in any of the above mentioned jurisdictions or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company referred to on this website have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act“), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.

All persons residing outside of the above mentioned jurisdictions who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Neither the Company, ABG Sundal Collier or Pareto Securities assumes any responsibility if there is a violation of applicable law and regulations by any person.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this website.

Access to electronic versions of these materials is being made available on this website by the Company in good faith and for information purposes only.


By clicking “Confirm” you confirm and certify that:

  • You are not a resident of or physically present in any of the above jurisdictions or any other restricted jurisdiction and are not a U.S. person (as defined in Regulation S under the Securities Act); and
  • you are either:
    1. a resident of, or physically present in, Sweden;
    2. if resident or physically present in a Member State of the European Economic Area other than Sweden, a qualified investor as defined in Regulation (EU) 2017/1129 (the “Prospectus Regulation” of the European parliament and of the council; or
    3. otherwise authorized to access this information pursuant to applicable laws or regulations.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]